Study on Pharmacokinetic Dynamics in Blood and Tissues of Continuous Administration of Beta-Lactam Antimicrobial Agents
- Conditions
- Diseases that are eligible for standby lower gastrointestinal (ileum, colon, rectum, anus) surgery.
- Registration Number
- JPRN-jRCTs061230082
- Lead Sponsor
- Ohge Hiroki
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 40
1. Standby surgical patients for the lower gastrointestinal tract (whether open or laparoscopic surgery)
2. Patients over 18 years old
3. Patients who give their written consent to participate in this study
1. Patients with a history of allergy to meropenem, tazobactam piperacillin, tazobactam ceftarosan, cefepime, or metronidazole
2. Patients with a history of allergy to beta-lactam antibacterial agents
3. Patients with impaired renal function whose creatinine clearance estimated by the Cockloft-Gault equation is less than 30 ml/min
4. Patients who are participating or intend to participate in other clinical studies while participating in this study
5. Patients currently using sodium valproate
6. Pregnant or lactating patients
7. Patients who are judged by the principal investigator or subinvestigator to be unjustly disadvantaged by participating in the study.
8. Patients whose participation in the research is judged by the principal investigator or subinvestigator to cause difficulty in conducting or evaluating this clinical research.
9. Employees of the Principal Investigators, etc., or of the institution who are directly involved in this or other clinical research, or family members of such employees or Principal Investigators, etc.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Pharmacokinetic parameters (Cmax, AUC, T1/2, Tmax) of each drug in plasma, peritoneal fluid and abdominal tissues (peritoneum and subcutaneous adipose tissue)
- Secondary Outcome Measures
Name Time Method